Dotmatics released its flagship multimodal drug discovery platform named Luma in October 2023, a low-code SaaS platform that aggregates relevant data across instruments and software into clean data structures for AI and ML-based analysis. In April 2025, Siemens announced it will acquire Dotmatics for $5.1B from Insight Partners, validating the company's strategic position as the leader in AI-driven R&D platform consolidation.
Cyborg Score Rationale
Dotmatics is trusted by more than 2 million researchers globally, commands an overwhelming market share in scientific software, and has achieved a $5.1B acquisition by an industrial conglomerate. The company's comprehensive product ecosystem, AI-native platform, and near-universal adoption across biopharma create durable competitive advantages.
Top Insights
Dotmatics has created the world's most comprehensive digital science platform with best-of-breed software applications already used by more than 2 million scientists, together in a single ecosystem united by a powerful, flexible enterprise data platform.
Luma, released in October 2023, is a low-code SaaS platform that aggregates relevant data across instruments and software into clean data structures for AI and ML-based analysis.
Luma Lab Connect allows R&D labs to automatically collect and manage all of their data from instruments and other data sources, eliminating manual processes and streamlining connectivity without requiring coding expertise.
In August 2024, Dotmatics made a significant minority investment in BioGlyph, a startup developing software for modeling multispecific antibodies that bind to two or more antigens.
Named Competitors
Benchling — Cloud-based ELN and LIMS for biotech R&D
ChemDraw — Molecular modeling and chemical structure drawing software
Biovia — Materials science and chemistry R&D software suite
Summalogic — Scientific data integration and analytics platform
Recent Developments
(April 2025) Siemens announced acquisition of Dotmatics for $5.1B, with deal completed three months later
(December 2025) Brian Lee named CEO after Thomas Swalla's departure
(August 2024) Dotmatics invested in BioGlyph for multispecific antibody modeling software
(October 2023) Released Luma, an AI-native multimodal drug discovery platform
Open the full interactive Dotmatics report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.